A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma. - El-Khoueiry AB; Kim RD; Harris WP; Sung MW; Waldschmidt D; Cabrera R; Garosi VL; Ploeger BA; Zebger-Gong H; Brennan BJ; Wang YA; Mueller U; et al. (Hepatology (Baltimore, Md.), 2026)